Subscribe
shutterstock_529874140_steven_frame
Steven Frame / Shutterstock.com
11 January 2021AmericasRory O'Neill

SCOTUS weighs future of assignor estoppel

The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Roche urges SCOTUS to cancel Illumina patent win
8 January 2021   Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Americas
Roche urges SCOTUS to cancel Illumina patent win
8 January 2021   Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More on this story

Americas
Roche urges SCOTUS to cancel Illumina patent win
8 January 2021   Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility